{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T14:49:37Z","timestamp":1786632577399,"version":"build-2736575974"},"reference-count":114,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100020206","name":"Health Commission of Shandong Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020206","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD) affects approximately one-third of adults worldwide and is increasingly recognized as a multisystem disorder. In addition to hepatic and cardiometabolic complications, many patients report fatigue, depression, anxiety, sleep disturbance, and subjective cognitive complaints. These manifestations are clinically important but correlate inconsistently with liver histology and may arise from several interacting mechanisms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To critically synthesize evidence on the liver\u2013gut\u2013brain axis in MASLD, distinguish established pathways from indirect or preclinical hypotheses, and evaluate implications for biomarkers, patient assessment, and treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PubMed was searched through July 15, 2026 using combinations of terms related to MASLD\/MASH, intestinal barrier function, gut microbiota, autonomic and stress signaling, hepatic inflammation and fibrosis, neuroinflammation, cognition, biomarkers, and treatment. Guidelines, randomized trials, prospective human studies, systematic reviews, and mechanistically informative experimental studies were prioritized. Evidence derived from cirrhosis, hepatic encephalopathy, other diseases, or animal models is explicitly identified.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The axis comprises neural, endocrine, immune, and metabolic communication. Stress-related hypothalamic\u2013pituitary\u2013adrenal and sympathetic activation may influence behavior, adipose tissue, intestinal motility, mucosal immunity, and epithelial integrity. Barrier dysfunction can increase portal exposure to microbial products that activate hepatic inflammatory pathways and aggravate insulin resistance. Conversely, hepatic and intestinal cytokines, bile acids, hepatokines, and microbial metabolites may signal at vascular and neural interfaces, although direct causal evidence for brain effects in noncirrhotic MASLD remains limited. Lifestyle and cardiometabolic risk management remain foundational. Resmetirom and semaglutide have regulatory indications for selected adults with noncirrhotic MASH and moderate-to-advanced fibrosis, whereas microbiota-directed therapies and neuromodulation remain investigational.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The liver\u2013gut\u2013brain axis is a useful integrative framework, but its component pathways have unequal evidentiary support. Longitudinal human studies using standardized hepatic, microbial, inflammatory, autonomic, and neurobehavioral outcomes are required before axis-based biomarkers or endotypes can guide routine care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1911290","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T14:07:16Z","timestamp":1786630036000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The liver\u2013gut\u2013brain axis in metabolic dysfunction-associated steatotic liver disease: bidirectional communication, clinical implications, and future perspectives"],"prefix":"10.3389","volume":"17","author":[{"given":"Yulian","family":"Ren","sequence":"first","affiliation":[{"name":"Department of Hepatobiliary Medicine, Affiliated Hospital of Shandong University of Traditional Chinese Medicine","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongqing","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Medicine, Affiliated Hospital of Shandong University of Traditional Chinese Medicine","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Medicine, Affiliated Hospital of Shandong University of Traditional Chinese Medicine","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Medicine, Affiliated Hospital of Shandong University of Traditional Chinese Medicine","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianqing","family":"Meng","sequence":"additional","affiliation":[{"name":"Infection Control Office, Affiliated Hospital of Shandong University of Traditional Chinese Medicine","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2023.101133","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"29","author":"Rinella","year":"2024","journal-title":"Ann Hepatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2023.0277","article-title":"Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity","volume":"29","author":"Kim","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/dom.70659","article-title":"Obesity and metabolic dysfunction-associated steatotic liver disease (MASLD): A literature review on pathophysiology and treatment","volume":"28","author":"Romanos","year":"2026","journal-title":"Diabetes Obes Metab"},{"key":"B6","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","year":"2024","journal-title":"J Hepatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1357664","article-title":"Non-alcoholic fatty liver disease and coexisting depression, anxiety and\/or stress in adults: a systematic review and meta-analysis","volume":"15","author":"Shea","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2024.1524555","article-title":"Body and mind: how obesity triggers neuropsychiatric and neurodegenerative disorders","volume":"15","author":"Pirozzi","year":"2024","journal-title":"Front Psychiatry"},{"key":"B10","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/s41392-023-01673-4","article-title":"Gut liver brain axis in diseases: the implications for therapeutic interventions","volume":"8","author":"Yan","year":"2023","journal-title":"Signal Transduct Tgt Ther"},{"key":"B11","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41392-024-01743-1","article-title":"Microbiota-gut-brain axis and its therapeutic applications in neurodegenerative diseases","volume":"9","author":"Loh","year":"2024","journal-title":"Signal Transduct Tgt Ther"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25147621","article-title":"Metabolic crosstalk between liver and brain: from diseases to mechanisms","volume":"25","author":"Yang","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B13","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3390\/metabo12010050","article-title":"Gut microbiota metabolites in major depressive disorder-deep insights into their pathophysiological role and potential translational applications","volume":"12","author":"Ortega","year":"2022","journal-title":"Metabolites"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-021-00677-w","article-title":"Role of the gut-brain axis in energy and glucose metabolism","volume":"54","author":"Wachsmuth","year":"2022","journal-title":"Exp Mol Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"eabe6729","DOI":"10.1126\/science.abe6729","article-title":"Enterically derived high-density lipoprotein restrains liver injury through the portal vein","volume":"373","author":"Han","year":"2021","journal-title":"Science"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-023-00771-6","article-title":"Gut-liver axis: barriers and functional circuits","volume":"20","author":"Pabst","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s11605-021-05188-7","article-title":"The role of gut-derived lipopolysaccharides and the intestinal barrier in fatty liver diseases","volume":"26","author":"An","year":"2022","journal-title":"J Gastrointest Surg"},{"key":"B18","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3390\/biom12010056","article-title":"Understanding the role of the gut microbiome and microbial metabolites in non-alcoholic fatty liver disease: current evidence and perspectives","volume":"12","author":"Vallianou","year":"2021","journal-title":"Biomolecules"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31651","article-title":"Targeting the four pillars of enterohepatic bile salt cycling; lessons from genetics and pharmacology","volume":"73","author":"Kunst","year":"2021","journal-title":"Hepatology"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2023.2172671","article-title":"Bile acids as modulators of gut microbiota composition and function","volume":"15","author":"Larabi","year":"2023","journal-title":"Gut Microbes"},{"key":"B21","doi-asserted-by":"publisher","first-page":"6046","DOI":"10.3390\/ijms23116046","article-title":"Molecular basis of bile acid-FXR-FGF15\/19 signaling axis","volume":"23","author":"Katafuchi","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B22","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41392-024-01811-6","article-title":"Bile acid metabolism and signaling in health and disease: molecular mechanisms and therapeutic targets","volume":"9","author":"Fleishman","year":"2024","journal-title":"Signal Transduct Tgt Ther"},{"key":"B23","doi-asserted-by":"publisher","first-page":"5982","DOI":"10.3390\/ijms21175982","article-title":"Bile acid signaling in neurodegenerative and neurological disorders","volume":"21","author":"Grant","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B24","doi-asserted-by":"publisher","first-page":"a034199","DOI":"10.1101\/cshperspect.a034199","article-title":"Vagus nerve stimulation at the interface of brain-gut interactions","volume":"9","author":"Bonaz","year":"2019","journal-title":"Cold Spring Harb Perspect Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1146\/annurev-immunol-042617-053158","article-title":"Molecular and functional neuroscience in immunity","volume":"36","author":"Pavlov","year":"2018","journal-title":"Annu Rev Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-024-01014-8","article-title":"Short-chain fatty acids: linking diet, the microbiome and immunity","volume":"24","author":"Mann","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1169624","article-title":"Short-chain fatty acids, secondary bile acids and indoles: gut microbial metabolites with effects on enteroendocrine cell function and their potential as therapies for metabolic disease","volume":"14","author":"Masse","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1515\/revneuro-2024-0065","article-title":"Neurobiological mechanisms in the kynurenine pathway and major depressive disorder","volume":"36","author":"Bertollo","year":"2025","journal-title":"Rev Neurosci"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.2147\/JMDH.S367591","article-title":"Intestinal flora derived metabolites affect the occurrence and development of cardiovascular disease","volume":"15","author":"Wen","year":"2022","journal-title":"J Multidiscip Healthc"},{"key":"B30","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13024-022-00548-6","article-title":"Microbial-derived metabolites as a risk factor of age-related cognitive decline and dementia","volume":"17","author":"Connell","year":"2022","journal-title":"Mol Neurodegener"},{"key":"B31","doi-asserted-by":"publisher","first-page":"15732","DOI":"10.3390\/ijms242115732","article-title":"Cholinergic polarization of human macrophages","volume":"24","author":"Roa-Vidal","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-023-03001-7","article-title":"Cholinergic signaling via the \u03b17 nicotinic acetylcholine receptor regulates the migration of monocyte-derived macrophages during acute inflammation","volume":"21","author":"Keever","year":"2024","journal-title":"J Neuroinflamm"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2025.1499202","article-title":"Advances in intestinal epithelium and gut microbiota interaction","volume":"16","author":"Yang","year":"2025","journal-title":"Front Microbiol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.871713","article-title":"The role of intestinal mucosal barrier in autoimmune disease: A potential target","volume":"13","author":"An","year":"2022","journal-title":"Front Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1490929","article-title":"The role of intestinal flora in metabolic dysfunction-associated steatotic liver disease and treatment strategies","volume":"11","author":"Wang","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2024.2331460","article-title":"Breaking the barriers: the role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD)","volume":"16","author":"Bened\u00e9-Ubieto","year":"2024","journal-title":"Gut Microbes"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.594150","article-title":"Role of metabolic endotoxemia in systemic inflammation and potential interventions","volume":"11","author":"Mohammad","year":"2020","journal-title":"Front Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1618275","article-title":"Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): the interplay of gut microbiome, insulin resistance, and diabetes","volume":"12","author":"Dua","year":"2025","journal-title":"Front Med (Lausanne)"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2025.101777","article-title":"From gut to liver: Exploring the crosstalk between gut-liver axis and oxidative stress in metabolic dysfunction-associated steatotic liver disease","volume":"30","author":"Zhou","year":"2025","journal-title":"Ann Hepatol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/s42255-024-01177-7","article-title":"Intestinal TM6SF2 protects against metabolic dysfunction-associated steatohepatitis through the gut-liver axis","volume":"7","author":"Zhang","year":"2025","journal-title":"Nat Metab"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000042476","article-title":"Linking gut permeability to liver steatosis: Noninvasive biomarker evaluation in MASLD patients - a prospective cross-sectional study","volume":"104","author":"Dumitru","year":"2025","journal-title":"Med (Baltimore)"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000004189","article-title":"Microbial translocation and gut damage is associated with hepatic fibrosis but not steatosis in women with and without HIV","volume":"39","author":"Duarte","year":"2025","journal-title":"AIDS"},{"key":"B43","doi-asserted-by":"publisher","first-page":"371","DOI":"10.3390\/antibiotics14040371","article-title":"The impact of antibiotic therapy on intestinal microbiota: dysbiosis, antibiotic resistance, and restoration strategies","volume":"14","author":"Cusumano","year":"2025","journal-title":"Antibiotics (Basel)"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.06.012","article-title":"Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease - novel insights into cellular communication circuits","volume":"77","author":"Peiseler","year":"2022","journal-title":"J Hepatol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"e186420","DOI":"10.1172\/JCI186420","article-title":"MASH: the nexus of metabolism, inflammation, and fibrosis","volume":"135","author":"Steinberg","year":"2025","journal-title":"J Clin Invest"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00639-3","article-title":"Immune cell-mediated features of non-alcoholic steatohepatitis","volume":"22","author":"Huby","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.3390\/ijms20061295","article-title":"Interleukin-1 receptor antagonist modulates liver inflammation and fibrosis in mice in a model-dependent manner","volume":"20","author":"Meier","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.867940","article-title":"Hepatic stellate cell-immune interactions in NASH","volume":"13","author":"Carter","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.11.311","article-title":"Mechanisms of fibrosis development in nonalcoholic steatohepatitis","volume":"158","author":"Schwabe","year":"2020","journal-title":"Gastroenterology"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25147873","article-title":"Liver fibrosis: from basic science towards clinical progress, focusing on the central role of hepatic stellate cells","volume":"25","author":"Akk\u0131z","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2024.114193","article-title":"Signalling of the neuropeptide calcitonin gene-related peptide (CGRP) through RAMP1 promotes liver fibrosis via TGF\u03b21\/Smad2 and YAP pathways","volume":"442","author":"Wang","year":"2024","journal-title":"Exp Cell Res"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.7150\/jca.59291","article-title":"\u03b2-arrestin2 regulating \u03b22-adrenergic receptor signaling in hepatic stellate cells contributes to hepatocellular carcinoma progression","volume":"12","author":"Li","year":"2021","journal-title":"J Cancer"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e33741","article-title":"Extracellular vesicles-derived ferritin from lipid-induced hepatocytes regulates activation of hepatic stellate cells","volume":"10","author":"Sun","year":"2024","journal-title":"Heliyon"},{"key":"B54","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/jcp.30915","article-title":"Intercellular communication among liver cells in the perisinusoidal space of the injured liver: Pathophysiology and therapeutic directions","volume":"238","author":"Ezhilarasan","year":"2023","journal-title":"J Cell Physiol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101401","article-title":"p63 controls metabolic activation of hepatic stellate cells and fibrosis via an HER2-ACC1 pathway","volume":"5","author":"Fondevila","year":"2024","journal-title":"Cell Rep Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2024.116044","article-title":"LncRNA SNHG11 reprograms glutaminolysis in hepatic stellate cells via Wnt\/\u03b2-catenin\/GLS axis","volume":"221","author":"Ying","year":"2024","journal-title":"Biochem Pharmacol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2024.05.003","article-title":"Metabolic reprogramming in liver fibrosis","volume":"36","author":"Horn","year":"2024","journal-title":"Cell Metab"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000762","article-title":"Neutrophil extracellular traps promote MASH fibrosis by metabolic reprogramming of HSC","volume":"81","author":"Xia","year":"2025","journal-title":"Hepatology"},{"key":"B59","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1136\/gutjnl-2021-324305","article-title":"Novel therapeutic targets for cholestatic and fatty liver disease","volume":"71","author":"Trauner","year":"2022","journal-title":"Gut"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.634539","article-title":"Evolutionary significance of the neuroendocrine stress axis on vertebrate immunity and the influence of the microbiome on early-life stress regulation and health outcomes","volume":"12","author":"Ortega","year":"2021","journal-title":"Front Microbiol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1130689","article-title":"Signalling cognition: the gut microbiota and hypothalamic-pituitary-adrenal axis","volume":"14","author":"Rusch","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1007\/s13205-025-04468-2","article-title":"Implicating neuroinflammation in hippocampus, prefrontal cortex and amygdala with cognitive deficit: a narrative review","volume":"15","author":"Blossom","year":"2025","journal-title":"3 Biotech"},{"key":"B63","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s12264-025-01571-5","article-title":"Research progress on the biological function and homeostatic disruption of microglia in the pathogenesis of major depressive disorder","volume":"42","author":"Kong","year":"2026","journal-title":"Neurosci Bull"},{"key":"B64","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12974-020-1705-z","article-title":"The progress of gut microbiome research related to brain disorders","volume":"17","author":"Zhu","year":"2020","journal-title":"J Neuroinflamm"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.796288","article-title":"Gut microbiota interact with the brain through systemic chronic inflammation: Implications on neuroinflammation, neurodegeneration, and aging","volume":"13","author":"Mou","year":"2022","journal-title":"Front Immunol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.2174\/1570159X21666221115150253","article-title":"The interplay between meningeal lymphatic vessels and neuroinflammation in neurodegenerative diseases","volume":"22","author":"Chen","year":"2024","journal-title":"Curr Neuropharmacol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1042\/CS20220697","article-title":"Biological tuners to reshape the bile acid pool for therapeutic purposes in non-alcoholic fatty liver disease","volume":"137","author":"Gillard","year":"2023","journal-title":"Clin Sci (Lond)"},{"key":"B68","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1186\/s12944-025-02728-x","article-title":"Liver fat mediates hippocampal-orbitofrontal reward circuit disruption and cognitive-emotional impairments in MASLD","volume":"24","author":"Wu","year":"2025","journal-title":"Lipids Health Dis"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03405-9","article-title":"The gut-brain axis underlying hepatic encephalopathy in liver cirrhosis","volume":"31","author":"He","year":"2025","journal-title":"Nat Med"},{"key":"B70","doi-asserted-by":"publisher","first-page":"14727","DOI":"10.3390\/ijms241914727","article-title":"Neurofilament light chain protein in plasma and extracellular vesicles is associated with minimal hepatic encephalopathy and responses to rifaximin treatment in cirrhotic patients","volume":"24","author":"Fiorillo","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B71","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41522-022-00352-6","article-title":"Host-microbiome interactions: Gut-liver axis and its connection with other organs","volume":"8","author":"Anand","year":"2022","journal-title":"NPJ Biofilms Microbiomes"},{"key":"B72","doi-asserted-by":"publisher","first-page":"3694","DOI":"10.3390\/ijms25073694","article-title":"Underlying mechanisms behind the brain-gut-liver axis and metabolic-associated fatty liver disease (MAFLD): An update","volume":"25","author":"De C\u00f3l","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-025-01089-1","article-title":"Gut microbiome in metabolic dysfunction-associated steatotic liver disease and associated hepatocellular carcinoma","volume":"22","author":"Lau","year":"2025","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.3390\/nu16071054","article-title":"The power of psychobiotics in depression: A modern approach through the microbiota-gut-brain axis: A literature review","volume":"16","author":"Dziedzic","year":"2024","journal-title":"Nutrients"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.cmet.2017.04.001","article-title":"Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease","volume":"25","author":"Loomba","year":"2017","journal-title":"Cell Metab"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.3390\/nu16121800","article-title":"Distinct gut microbial signature and host genetic variants in association with liver fibrosis severity in patients with MASLD","volume":"16","author":"Satthawiwat","year":"2024","journal-title":"Nutrients"},{"key":"B77","doi-asserted-by":"publisher","first-page":"e0728","DOI":"10.1097\/HC9.0000000000000728","article-title":"A comprehensive evaluation of candidate genetic polymorphisms in a large histologically characterized MASLD cohort using a novel framework","volume":"9","author":"Hakim","year":"2025","journal-title":"Hepatol Commun"},{"key":"B78","doi-asserted-by":"publisher","first-page":"5164","DOI":"10.3390\/ijms26115164","article-title":"Polygenic risk score for metabolic dysfunction-associated steatotic liver disease and steatohepatitis: A narrative review","volume":"26","author":"Kanda","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B79","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s00203-023-03752-0","article-title":"Immunology of gut microbiome and liver in non-alcoholic fatty liver disease (NAFLD): mechanisms, bacteria, and novel therapeutic targets","volume":"206","author":"Gruzdev","year":"2024","journal-title":"Arch Microbiol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"960","DOI":"10.3390\/cells13110960","article-title":"Combined insults of a MASH diet and alcohol binges activate intercellular communication and neutrophil recruitment via the NLRP3-IL-1\u03b2 axis in the liver","volume":"13","author":"Babuta","year":"2024","journal-title":"Cells"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-024-02096-w","article-title":"iATT liver fat quantification for steatosis grading by referring to MRI proton density fat fraction: a multicenter study","volume":"59","author":"Hirooka","year":"2024","journal-title":"J Gastroenterol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101220","article-title":"Molecular imaging of macrophage composition and dynamics in MASLD","volume":"6","author":"Yang","year":"2024","journal-title":"JHEP Rep"},{"key":"B83","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s44324-025-00055-4","article-title":"Longitudinal association of metabolic dysfunction-associated fatty liver disease, serum metabolites, with cognitive function trajectories","volume":"3","author":"Wang","year":"2025","journal-title":"NPJ Metab Health Dis"},{"key":"B84","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s40168-024-01924-8","article-title":"Akkermansia muciniphila improve cognitive dysfunction by regulating BDNF and serotonin pathway in gut-liver-brain axis","volume":"12","author":"Kang","year":"2024","journal-title":"Microbiome"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2024.1421007","article-title":"Bifidobacterium pseudonumeratum W112 alleviated depressive and liver injury symptoms induced by chronic unpredictable mild stress via gut-liver-brain axis","volume":"11","author":"Zhao","year":"2024","journal-title":"Front Nutr"},{"key":"B86","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.gastha.2023.08.019","article-title":"A novel prescription digital therapeutic option for the treatment of metabolic dysfunction-associated steatotic liver disease","volume":"3","author":"Alkhouri","year":"2024","journal-title":"Gastro Hep Adv"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1002\/ueg2.12534","article-title":"Fibroblast growth factor 21 is a hepatokine involved in MASLD progression","volume":"12","author":"Gallego-Dur\u00e1n","year":"2024","journal-title":"United Eur Gastroenterol J"},{"key":"B88","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s43856-025-01317-4","article-title":"Association between mental health and MASLD molecular insights through metabolomics","volume":"6","author":"Yang","year":"2025","journal-title":"Commun Med (Lond)"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1177\/11786469261423510","article-title":"Altered tryptophan-kynurenine pathway and low-grade inflammation in metabolic dysfunction-associated steatotic liver disease (MASLD): Insights from LC-MS\/MS-based metabolite profiling","volume":"19","author":"\u00dcnal","year":"2026","journal-title":"Int J Tryptophan Res"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000001539","article-title":"Bile acid signaling in MASLD: From pathogenesis to therapeutic applications","author":"Simbrunner","year":"2025","journal-title":"Hepatology"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00346.2024","article-title":"Plasma and fecal bile acids profiles in metabolic dysfunction-associated steatotic liver disease with advanced fibrosis","volume":"329","author":"Pradeau","year":"2025","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30163","article-title":"ADAPT: An algorithm incorporating PRO-C3 accurately identifies patients with NAFLD and advanced fibrosis","volume":"69","author":"Daniels","year":"2019","journal-title":"Hepatology"},{"key":"B93","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1053\/j.gastro.2025.02.044","article-title":"Global consensus recommendations for metabolic dysfunction-associated steatotic liver disease and steatohepatitis","volume":"169","author":"Younossi","year":"2025","journal-title":"Gastroenterology"},{"key":"B94","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.3390\/nu15092150","article-title":"The effects of the Mediterranean diet on health and gut microbiota","volume":"15","author":"Barber","year":"2023","journal-title":"Nutrients"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15264","article-title":"Impact of a Mediterranean diet on hepatic and metabolic outcomes in non-alcoholic fatty liver disease: The MEDINA randomised controlled trial","volume":"42","author":"George","year":"2022","journal-title":"Liver Int"},{"key":"B96","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.3390\/nu14091773","article-title":"A low glycemic index Mediterranean diet combined with aerobic physical activity rearranges the gut microbiota signature in NAFLD patients","volume":"14","author":"Calabrese","year":"2022","journal-title":"Nutrients"},{"key":"B97","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.3390\/biomedicines11123255","article-title":"Vagal stimulation ameliorates non-alcoholic fatty liver disease in rats","volume":"11","author":"Elkattawy","year":"2023","journal-title":"Biomedicines"},{"key":"B98","doi-asserted-by":"publisher","first-page":"21042","DOI":"10.1038\/s41598-024-72139-y","article-title":"Transcutaneous vagus nerve stimulation has no anti-inflammatory effect in diabetes","volume":"14","author":"Okdahl","year":"2024","journal-title":"Sci Rep"},{"key":"B99","doi-asserted-by":"publisher","first-page":"5688","DOI":"10.1038\/s41598-019-42059-3","article-title":"Randomized, double-blind, placebo-controlled study of a multispecies probiotic mixture in nonalcoholic fatty liver disease","volume":"9","author":"Ahn","year":"2019","journal-title":"Sci Rep"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/j.crfs.2025.101138","article-title":"Probiotics as a therapeutic strategy for metabolic dysfunction-associated steatotic liver disease: A systematic review and meta-analysis","volume":"11","author":"Lu","year":"2025","journal-title":"Curr Res Food Sci"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000000661","article-title":"Allogenic fecal microbiota transplantation in patients with nonalcoholic fatty liver disease improves abnormal small intestinal permeability: A randomized control trial","volume":"115","author":"Craven","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"B102","unstructured":"FDA Approves First Treatment for Patients With Liver Scarring Due to Fatty Liver Disease\n          \n          \n          \n          2024"},{"key":"B103","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1111\/liv.70256","article-title":"Glucagon-like peptide-1 receptor agonists improve MASH and liver fibrosis: A meta-analysis of randomised controlled trials","volume":"45","author":"Mantovani","year":"2025","journal-title":"Liver Int"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"key":"B107","unstructured":"FDA Approves Treatment for Serious Liver Disease Known as MASH\n          \n          \n          \n          2025"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"B109","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N Engl J Med"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15006","article-title":"Empagliflozin versus sitagliptin for ameliorating intrahepatic lipid content and tissue-specific insulin sensitivity in patients with early-stage type 2 diabetes with non-alcoholic fatty liver disease: A prospective randomized study","volume":"25","author":"Hiruma","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.07.014","article-title":"Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis","volume":"79","author":"Sanyal","year":"2023","journal-title":"J Hepatol"},{"key":"B112","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/hep.31205","article-title":"Cilofexor, a nonsteroidal FXR agonist, in patients with noncirrhotic NASH: A phase 2 randomized controlled trial","volume":"72","author":"Patel","year":"2020","journal-title":"Hepatology"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.03.038","article-title":"An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH","volume":"79","author":"Tacke","year":"2023","journal-title":"J Hepatol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.26502\/acbr.50170450","article-title":"Impact of antidepressants on weight gain: Underlying mechanisms and mitigation strategies","volume":"9","author":"Mouawad","year":"2025","journal-title":"Arch Clin BioMed Res"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1911290\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T14:07:21Z","timestamp":1786630041000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1911290\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":114,"alternative-id":["10.3389\/fendo.2026.1911290"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1911290","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,13]]},"article-number":"1911290"}}